THE ROLE OF CFTR MUTATIONS IN CAUSING CYSTIC FIBROSIS (CF)

Similar documents
THE ROLE OF CFTR MUTATIONS IN CAUSING CYSTIC FIBROSIS (CF)

A Quick Guide to the. I507del. Mutation CFTR SCIENCE

A Quick Guide to the G A. Mutation CFTR SCIENCE

A Quick Guide to the. CFTRdele2,3. Mutation CFTR SCIENCE

A Quick Guide to the 621+1G T. Mutation CFTR SCIENCE

CYSTIC FIBROSIS (CF) COMPLICATIONS BEYOND THE LUNGS. A Resource for the CF Center Care Team

CYSTIC FIBROSIS (CF): THE CHALLENGE OF EARLY, SYSTEMIC PROGRESSION

Transformational Treatments. PRESTON W. CAMPBELL, III, M.D. Executive Vice President for Medical Affairs

"Management and Treatment of Patients with Cystic fibrosis (CF)

Symdeko. Symdeko (tezacaftor and ivacaftor) Description

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Kalydeco. Kalydeco (ivacaftor) Description

Evaluation of Patients with Diffuse Bronchiectasis

The Future of CF Therapy

Pharmacy Policy Bulletin

UNDERSTANDING THE EARLY, SYSTEMIC PROGRESSION OF CYSTIC FIBROSIS (CF) A Resource for the CF Center Care Team

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Case Study What is the Relationship Between the Cell Membrane and Cystic Fibrosis?

UNDERSTANDING THE EARLY, SYSTEMIC PROGRESSION OF CYSTIC FIBROSIS (CF)

Cystic fibrosis (CF) is the most frequent. Ivacaftor treatment in patients with cystic REVIEW. Isabelle Sermet-Gaudelus

Cystic Fibrosis Foundation Patient Registry 2013

A Case of Cystic Fibrosis

You Can Observe a Lot By Just Watching. Wayne J. Morgan, MD, CM

REGISTRY ANNUAL DATA REPORT

Respiratory Pharmacology: Treatment of Cystic Fibrosis

UK Cystic Fibrosis Registry 2014 Annual Data Report

Cystic Fibrosis: Progress in Treatment Management. Patrick A. Flume, M.D. Medical University of South Carolina

A Genetic Approach to the Treatment of Cystic Fibrosis

GENETIC TESTING: IN WHOM AND WHEN

Cystic Fibrosis the future

Supplementary appendix

Cost-effectiveness of Ivacaftor (Kalydeco ) for the treatment of cystic fibrosis in patients age 6 years and older who have the G551D mutation

Pharmacogenomics in Rare Diseases: Development Strategy for Ivacaftor as a Therapy for Cystic Fibrosis

Orkambi. Orkambi (lumacaftor/ivacaftor) Description

What is the inheritance pattern (e.g., autosomal, sex-linked, dominant, recessive, etc.)?

Key Points: References: Canadian data from the Canadian Cystic Fibrosis Registry 2015 Annual Report normal

A treatment option for patients with CF who have responsive mutations

6.2.1 Exocrine pancreatic insufficiency

The Deciphering Development Disorders (DDD) project: What a genomic approach can achieve

Atypical cystic fibrosis: from the genetic causes to current and future treatments

CYSTIC FIBROSIS OBJECTIVES NO CONFLICT OF INTEREST TO DISCLOSE

Supplementary appendix

Lesson Overview. Human Genetic Disorders. Lesson Overview Human Genetic Disorders

Lesson Overview. Human Genetic Disorders. Lesson Overview Human Genetic Disorders

Recently, the cystic fibrosis (CF) community celebrated the 25th

Briefing Document. FDA Pulmonary - Allergy Drugs Advisory Committee

Drug Use Criteria: Ivacaftor (Kalydeco ) and Lumacaftor/Ivacaftor (Orkambi )

PA Update: Oral Cystic Fibrosis Modulators

Human Genetic Disorders. Lesson Overview. Lesson Overview Human Genetic Disorders

CFTR Genotype as a Predictor of Prognosis in Cystic Fibrosis*

Goals Basic defect Pathophysiology Clinical i l signs and symptoms Therapy

Diagnostic challenges after NBS for CF

Initiation Guide. Images not actual size.

Pediatrics Grand Rounds 13 November University of Texas Health Science Center at San Antonio. Learning Objectives

Lung function and disease severity in cystic fibrosis patients heterozygous for p.arg117his

Sample Test Report. Mayo Clinic GeneGuide. Report. Consumer Name DOB: 00/00/0000

Evening Case studies, Tuesday April 30, Vijay L. Grey McMaster University

Cystic Fibrosis Diagnosis and Treatment

Disclosures. Advances in the Management of Cystic Fibrosis: A Closer Look at the Roles of CFTR Modulation Therapy 10/28/2016

Application to be an additional provider for existing test on the NHS Directory of Molecular Genetic Testing Additional Provider form

North American Cystic Fibrosis Conference 27 October Noreen R Henig, MD Chief Development Officer ProQR Therapeutics

JULY 21, Genetics 101: SCN1A. Katie Angione, MS CGC Certified Genetic Counselor CHCO Neurology

Title: Lack of correlation between pulmonary disease and CFTR dysfunction in cystic fibrosis -- the case of 3791delC

Brand Name: Kalydeco. Generic: ivacaftor. Manufacturer 1 : Vertex Pharmaceuticals Incorporated

A guide to understanding variant classification

Cystic Fibrosis in Canada

A review of Cystic Fibrosis

IVACAFTOR THE ISRAELI EXPERIENCE ADI DAGAN MD THE ISRAELI CF CENTER SHEBA MEDICAL CENTER, TEL-HASHOMER

Genotypes and Phenotypes in Cystic Fibrosis and Cystic Fibrosis Transmembrane Regulator Related Disorders

Screen Positive Follow-up In The Clinic

Clinical Commissioning Policy: Ivacaftor for Cystic Fibrosis (named mutations)

Enabling CF Therapeutic Development

Pediatrics Grand Rounds 18 Sept University of Texas Health Science Center. + Disclosure. + Learning Objectives.

PULMONARY SURFACTANT, ALPHA 1 ANTITRYPSIN INHIBITOR DEFICIENCY, AND CYSTIC FIBROSIS DR. NABIL BASHIR BIOCHEMISTRY/RESPIRATORY SYSTEM

North American Cystic Fibrosis Conference 27 October Noreen R Henig, MD Chief Development Officer ProQR Therapeutics

E-BOOK # PANCREATIC ENZYMES FOR CYSTIC FIBROSIS ARCHIVE

Genetic Testing and Analysis. (858) MRN: Specimen: Saliva Received: 07/26/2016 GENETIC ANALYSIS REPORT

ivacaftor 150mg film-coated tablets (Kalydeco ) SMC No. (1193/16) Vertex Pharmaceuticals (Europe) Ltd

Refining the continuum of CFTR-associated disorders in the era of newborn screening

Cystic Fibrosis a) Diagnostic Dilemmas b) The New Problems. Dr Mark Rosenthal Royal Brompton Hospital London

Palliative and Supportive Care in Cystic Fibrosis

GLPG1837 in Subjects with Cystic Fibrosis (CF) and the G551D Mutation: results from a Phase II study (SAPHIRA1)

Counsyl Foresight Carrier Screen. Utmost confidence in every result

CLINICAL MEDICAL POLICY

PORT CFNZ National Data Registry ~ 1 ~

Cystic Fibrosis. Jennifer McDaniel, BS, RRT-NPS

Treating Cystic Fibrosis in Resource Poor Environment

THE JOURNAL OF PEDIATRICS

ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: October 3, ClinicalTrials.gov ID: NCT

Cystic Fibrosis. Cystic Fibrosis. Cystic Fibrosis 5/01/2011 CYSTIC FIBROSIS OF THE PANCREAS AND ITS RELATION TO CELIAC DISEASE. D ANDERSEN.

Supplementary Online Content

The Cystic Fibrosis Gene. about. CF is one of the most common genetic diseases that cause death in both children and

Prevalence of meconium ileus marks the severity of mutations of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene

At-A-Glance report 2014

EVOLVE GENETIC FERTILITY SCREENS

At-A-Glance report 2013

An Effective Model to Communicate Complex Genetic Information to Families and Health Care Providers

Human Genetic Disorders

HIMANSHU SHARMA. POSITION APPLIED FOR Postdoctoral Fellow

UNDERSTANDING HOW CYSTIC FIBROSIS (CF) PROGRESSES AND ITS IMPACT ON YOUR PATIENTS

Transcription:

THE ROLE OF CFTR MUTATIONS IN CAUSING CYSTIC FIBROSIS (CF) Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA 02210. Vertex and the Vertex triangle logo are registered trademarks of Vertex Pharmaceuticals Incorporated. 2018 Vertex Pharmaceuticals Incorporated VXR-US-20-02038(1) 11/2018 1 2018 Vertex Pharmaceuticals Incorporated

Overview CF is a complex, genetic disease CF occurs when a child inherits two copies of a CFTR gene mutation resulting in a CF genotype 1,2 CFTR protein activity is determined by CFTR protein quantity and function 1,3 In CF, there is a reduction in total CFTR protein activity leading to an imbalance of fluid and ions in organs throughout the body 1,3,4 Different CFTR mutations produce different effects on CFTR protein quantity and function 1,3,4 When patients and caregivers are educated about their genotype, they are empowered to be active partners in their own care 5 CFTR, cystic fibrosis transmembrane conductance regulator. References: 1. Boyle MP, De Boeck K. Lancet Resp Med. 2013;1(2):158-163. 2. Zielenski J. Respiration. 2000;67(2):117-133. 3. Derichs N. Eur Resp Rev. 2013;22(127):58-65. 4. Elborn JS. Lancet. 2016;388(10059):2519-2531. 5. Cystic Fibrosis News Today. https://www.cysticfibrosisnewstoday.com/2015/02/06/cf-trust-willpay-for-patients-to-know-their-specific-genotype. February 6, 2015. Accessed October 22, 2018. 2 2018 Vertex Pharmaceuticals Incorporated

CFTR proteins in normal cells 3 2018 Vertex Pharmaceuticals Incorporated

CFTR proteins: An important regulator of fluid and ion balance in organs throughout the body CFTR proteins are found on epithelial cell surfaces in organs throughout the body 1-4 Normally, CFTR protein channels transport ions, such as chloride and bicarbonate, through the epithelial cell surface in these organs 1-4 Maintaining water and salt balance at the epithelial cell surface requires an adequate quantity and function of CFTR proteins 5 Total CFTR activity can be defined as total ion transport mediated by CFTR protein channels at the cell surface. It is dependent on CFTR protein quantity and function 4,6 CFTR CFTR function quantity X = Channel-open Conductance probability X Total CFTR activity References: 1. Zielenski J. Respiration. 2000;67(2):117-133. 2. O Sullivan BP, Freedman SD. Lancet. 2009;373(9678):1891-1904. 3. MacDonald KD et al. Pediatr Drugs. 2007;9(1):1-10. 4. Derichs N. Eur Resp Rev. 2013;22(127):58-65. 5. Elborn JS. Lancet. 2016;388(10059):2519-2531. 6. Boyle MP, De Boeck K. Lancet Rep Med. 2013;1:158-163. 4 2018 Vertex Pharmaceuticals Incorporated

CFTR protein function is determined by channel-open probability and channel conductance Channel-open probability: the fraction of time that a single CFTR protein channel is open and transporting ions. 1 Channel conductance: rate at which ions move through open CFTR protein channels. 2 Status of a single channel over time 3* Normal CFTR channel-open probability 3 Normal CFTR channel conductance 1 *Based on in vitro experimentation. Reference: 1. Wang W, Linsdell P. Biochim Biophys Acta. 2012;1818(3):851-860. 2. Hwang TC, Kirk KL. Cold Spring Harb Perspect Med. 2013;3(1):a009498. 3. Bompadre SG et al. J Gen Physiol. 2007;129(4):285-298. 5 2018 Vertex Pharmaceuticals Incorporated

CFTR proteins reach the cell membrane through a multi-step process X X X X CFTR protein function and breakdown CFTR protein trafficking (delivery to the cell surface) CFTR protein synthesis CFTR mutations may affect different steps of this process to reduce CFTR quantity and/or function and reduce total CFTR protein activity 1,2 X X CFTR gene expression References: 1. Boyle MP, De Boeck K. Lancet Resp Med. 2013;1:158-163. 2. Derichs N. Eur Resp Rev. 2013;22(127):58-65. 6 2018 Vertex Pharmaceuticals Incorporated

The importance of understanding CFTR mutations and their nomenclature 7 2018 Vertex Pharmaceuticals Incorporated

CFTR mutations are inherited genetically If a person inherits 2 copies of a disease-causing CFTR mutation (one from each parent), CFTR protein dysfunction can occur 1 CFTR protein dysfunction impairs cellular chloride transport CF disease can be the result Reference: 1. Boyle MP, De Boeck K. Lancet Rep Med. 2013;1:158-163. 8 2018 Vertex Pharmaceuticals Incorporated

CFTR mutations can be referred to by different names Names of CFTR Mutations 1,2,3 Name Definition Utilization Legacy name (F508del) cdna name (c.1521_1523delctt) Commonly used colloquial nomenclature DNA sequence Used primarily in genetic clinics and diagnostic laboratories Used to identify mutations as listed in global sequence databases such as GenBank Protein name (p.phe508del) Amino acid sequence (three-letter code) Used to identify pathogenic mechanism of mutation based on altered protein synthesis Different naming conventions are used by researchers in publications, genetic clinics, and diagnostic laboratories References: 1. Cystic Fibrosis Foundation. Patient Registry Annual Data Report 2016. Bethesda, MD. 2017 Cystic Fibrosis Foundation. 2. Ogino S, et al. The Journal of molecular diagnostics:2007;9(1):1-6 3. NCBI GenBank. https://www.ncbi.nlm.nih.gov/genbank. Accessed October 25, 2018. 9 2018 Vertex Pharmaceuticals Incorporated

Certain CFTR mutations may affect CFTR quantity and/or function, reducing total CFTR activity Spectrum of phenotypes associated with total CFTR activity 1 People with 2 CFTR mutations resulting in loss of CFTR activity generally have a CF phenotype, which may include 1,2 Elevated sweat chloride (>60 mmol/l) Pancreatic insufficiency CBAVD Lung function decline over time Pseudomonas aeruginosa colonization Certain CFTR mutations result in some CFTR activity 1,2 Other CFTR mutations result in little to no CFTR activity 1,2 Adapted with permission from Castellani and Assael. CBAVD, congenital bilateral absence of vas deferens. References: 1. Castellani C, Assael BM. Cell Mol Life Sci. 2017;74:129-140. 2. Derichs N. Eur Resp Rev. 2013;22(127):58-65. 10 2018 Vertex Pharmaceuticals Incorporated

The effects of CFTR mutations on total CFTR activity 11 2018 Vertex Pharmaceuticals Incorporated

Different CFTR mutations produce different effects on CFTR protein quantity and function CFTR mutations are grouped into classes according to their effects on CFTR protein synthesis, trafficking, or function 1-3 CFTR CFTR function quantity X = Channel-open Conductance probability X Total CFTR activity Defective synthesis (Class I) Defective processing and trafficking (Class II) Defective gating (Class III) Defective conductance (Class IV) Decreased splicing (Class V) Decreased protein stability (Class VI) The top 25 mutations are comprised of those in classes I-V 4 References: 1. Derichs N. Eur Respir Rev. 2013;22(127):58-65. 2. Boyle MP, De Boeck K. Lancet Rep Med. 2013;1:158-163. 3. Zielenski J. Respiration. 2000;67(2):117-133. 4. Cystic Fibrosis Foundation. Patient Registry Annual Data Report 2016. Bethesda, MD. 2017 Cystic Fibrosis Foundation. 12 2018 Vertex Pharmaceuticals Incorporated

Examples of CFTR mutations that result in defective biosynthesis of the CFTR protein CFTR quantity CFTR function Total CFTR activity Defective synthesis yields no functional X Channel-open Conductance: probability: X = Little to none 1-3 CFTR protein 1-3 Little to none Little to none An absence of CFTR protein regardless of function since few to no CFTR proteins reach the surface... results in little to no total CFTR activity Examples (Class I) Legacy Name 4,5 cdna Name 4,5 Protein Name 4,5 Type 4 US Prevalence (%) 6 G542X c.1624g>t p.gly542x Nonsense 4.7 1717-1G-->A c.1585-1g>a No Protein Name Splice defect 1.6 3659delC c.3528delc p.lys1177serfsx15 Frameshift 0.7 References: 1. Derichs N. Eur Resp Rev. 2013;22(127):58-65. 2. Boyle MP, De Boeck K. Lancet Rep Med. 2013;1:158-163. 3. Zielenski J. Respiration. 2000;67(2):117-133. 4. Ogino S et al. J Mol Diagn. 2007;9(1):1-6. 5. NCBI ClinVar https://www.ncbi.nlm.nih.gov/clinvar/rcv000029523. Accessed October 25, 2018. 6. Cystic Fibrosis Foundation. Patient Registry Annual Data Report 2016. Bethesda, MD. 2017 Cystic Fibrosis Foundation. 13 2018 Vertex Pharmaceuticals Incorporated

Examples of CFTR mutations that result in defective processing and trafficking of the CFTR protein CFTR quantity CFTR function Total CFTR activity Defective processing and trafficking results in few CFTR proteins at cell surface 1-3 X Channel-open probability: Little to none Conductance: X = Little to none Little to none1-3 Significantly reduced CFTR protein regardless of function since few to no CFTR proteins reach the surface... results in little to no total CFTR activity Examples (Class II) Legacy Name cdna Name Protein Name Type 4 US Prevalence (%) 5 F508del c.1521_1523delctt p.phe508del Amino acid deletion 86.4 a N1303K c.3909c>g p.asn1303lys Missense 2.4 ahomozygous and heterozygous. References: 1. Derichs N. Eur Resp Rev. 2013;22(127):58-65. 2. Boyle MP, De Boeck K. Lancet Rep Med. 2013;1:158-163. 3. Zielenski J. Respiration. 2000;67(2):117 133. 4. Ogino S et al. J Mol Diagn. 2007;9(1):1-6. 5. Cystic Fibrosis Foundation. Patient Registry Annual Data Report 2016. Bethesda, MD. 2017 Cystic Fibrosis Foundation. 14 2018 Vertex Pharmaceuticals Incorporated

Example of CFTR mutations that reduce channel-open probability in the CFTR protein CFTR quantity CFTR function Total CFTR activity Defective Normal channel Conductance: X gating at cell X = Normal Little to none 1-3 membrane 1-3 Although CFTR protein quantity may be normal function is severely reduced due to decreased channel-open probability... results in little to no total CFTR activity Examples (Class III) Legacy Name cdna Name Protein Name Type 4 US Prevalence (%) 5 G551D c.1652g>a p.gly551asp Missense 4.4 References: 1. Derichs N. Eur Resp Rev. 2013;22(127):58-65. 2. Boyle MP, De Boeck K. Lancet Rep Med. 2013;1:158-163. 3. Zielenski J. Respiration. 2000;67(2):117 133. 4. Ogino S et al. J Mol Diagn. 2007;9(1):1-6. 5. Cystic Fibrosis Foundation. Patient Registry Annual Data Report 2016. Bethesda, MD. 2017 Cystic Fibrosis Foundation. 15 2018 Vertex Pharmaceuticals Incorporated

Example of CFTR mutations that result in a CFTR protein with defective conductance CFTR quantity CFTR function Total CFTR activity Normal X Channel-open Conductance: probability: X = Some Reduced 1-3 1-3 Normal Although CFTR protein quantity may be normal function is reduced due to decreased conductance... and results in some total CFTR activity Examples (Class IV) Legacy Name cdna Name Protein Name Type 4 US Prevalence (%) 5 R117H c.350g>a p.arg117his Missense 3.0 References: 1. Derichs N. Eur Resp Rev. 2013;22(127):58-65. 2. Boyle MP, De Boeck K. Lancet Rep Med. 2013;1:158-163. 3. Zielenski J. Respiration. 2000;67(2):117 133. 4. Ogino S et al. J Mol Diagn. 2007;9(1):1-6. 5. Cystic Fibrosis Foundation. Patient Registry Annual Data Report 2016. Bethesda, MD. 2017 Cystic Fibrosis Foundation. 16 2018 Vertex Pharmaceuticals Incorporated

Examples of CFTR mutations that result in some functional CFTR at the cell surface CFTR quantity CFTR function Total CFTR activity Reduced 1-3 X Channel-open Conductance: probability: X = Some Little to none 1-3 Little to none CFTR protein quantity is reduced even though CFTR function is not impaired... and results in some total CFTR activity Examples (Class V) Legacy Name cdna Name Protein Name Type 4,5 US prevalence (%) 5 3849+10kbC->T c.3717+12191c>t p.phe508del Splice defect 1.5 A455E c.1364c>a p.ala455glu Missense 0.6 References: 1. Derichs N. Eur Resp Rev. 2013;22(127):58-65. 2. Boyle MP, De Boeck K. Lancet Rep Med. 2013;1:158-163. 3. Zielenski J. Respiration. 2000;67(2):117 133. 4. Ogino S et al. J Mol Diagn. 2007;9(1):1-6. 5. Cystic Fibrosis Foundation. Patient Registry Annual Data Report 2016. Bethesda, MD. 2017 Cystic Fibrosis Foundation. 17 2018 Vertex Pharmaceuticals Incorporated

The importance of patients and caregivers knowing their CF genotype 18 2018 Vertex Pharmaceuticals Incorporated

Patients benefit from knowing their CF genotype Patients/Caregivers who are educated about their CF genotypes may be empowered to be active partners in their own care Patients/Caregivers who know about their genotype may 1 : Better understand their CF symptoms and how CF may progress Seek access to treatment plans that are most appropriate for them Actively participate in making care decisions with their doctor or healthcare team Be informed about research studies that may be an option for them Reference: 1. Cystic Fibrosis News Today. https://www.cysticfibrosisnewstoday.com/2015/02/06/cf-trust-will-pay-for-patients-to-know-their-specific-genotype. February 6, 2015. Accessed October 22, 2018. 19 2018 Vertex Pharmaceuticals Incorporated

Engaging patients and caregivers in conversations about CF Communicating with patients and/or caregivers about how their CF genotype can impact care and treatment decisions is important; but helping them understand the reasons can be challenging. Below are some points that can be useful when talking with patients/caregivers about their CF genotype: Consider discussing how: Every person with cystic fibrosis inherited two mutated CF-causing genes which together form a person s CF genotype 1 Different mutations impair CFTR function in different ways leading to variations in the symptoms, disease severity, and disease progression each person with CF experiences 2 Despite the variation in presentation, all genotypes experience disease progression, making personalized disease management important throughout a patient s lifetime 2,3 A care plan can also be personalized based on environment, physiology, patient and caregiver preferences, and lifestyle 4 The most important thing for the patient/caregiver to remember is that when the genotype is known, the care team can customize CF care and treatment plans to help optimize each patient s situation References: 1. Orenstein D et al. Cystic Fibrosis: A Guide for Patient and Family. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2004. 2. Zielenski J. Respiration. 2000;67(2):117 133. 3. McKone EF. J Cyst Fibros. 2015;14(5):580-586. doi:10.1016/j.jcf.2015.01.005. Epub 2015 Feb 3. 4. Feng L et al. Health Aff (Millwood). 2018;37(5):773-779. 20 2018 Vertex Pharmaceuticals Incorporated

Summary THE ROLE OF CFTR IN CF 21 2018 Vertex Pharmaceuticals Incorporated

Summary CFTR protein is an important cellular regulator in organs throughout the body 1,2 CFTR mutations result in a loss of total CFTR protein activity, which is the underlying cause of CF 1,2 Different types of CFTR mutations vary in their effects on CFTR protein quantity and/or function 2,3 Both CFTR mutations play a role in determining phenotype or disease severity 4 Discussing genotype with patients helps them understand their CF disease presentation and treatment options 5 References: 1. Boyle MP, De Boeck K. Lancet Rep Med. 2013;1:158-163. 2. Derichs N. Eur Resp Rev. 2013;22(127):58-65. 3. Cystic Fibrosis Foundation. Patient Registry Annual Data Report 2016. Bethesda, MD. 2017 Cystic Fibrosis Foundation. 4. Zielenski J. Respiration. 2000;67(2):117 133. 5. Feng L et al. Health Aff (Millwood). 2018;37(5):773-779. 22 2018 Vertex Pharmaceuticals Incorporated